Celgene opts not to proceed with anti-TIGIT antibody

13 June 2019

London and New York-listed Mereo BioPharma (AIM: MPH) will regain rights to etigilimab from Celgene (Nasdaq: CELG), as the American firm elected not to exercise an option on the candidate.

Etigilimab, an anti-TIGIT antibody, is one of two product candidates Mereo acquired through its April 2019 merger with OncoMed, a move which sent Mereo shares down sharply. Mereo stock has lost about 60% of its value in 2019.

Mereo, a clinical stage biotech focused on rare diseases, said that Celgene is handing back the candidate, “for strategic product portfolio considerations,” and that the firms are working to finalize the termination of the collaboration agreement.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK